Varenicline OTC Trial on Efficacy and Safety
common.study.values.description
“Varenicline OTC Trial on Efficacy and Safety”
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - 1.0mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Drug - 0.5mg Varenicline b.i.d.
Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
Drug - 0.0mg placebo Varenicline b.i.d.
Product that looks like active varenicline, but contains no active ingredient
participant.views.study.view.additional
participant.views.study.view.scientific-title
Varenicline OTC Trial on Efficacy and Safety
common.study.values.clinical-trial-id
NCT03557294
participant.views.study.view.id
PdyQnd
